More than 160 faculty and students filled Uris Auditorium Dec. 5 to hear doctoral candidates deliver bite-size presentations of their research in an entertaining way. The catch? They had to deliver their work in three minutes or less.
New study by The Rockefeller University and Weill Cornell Medicine investigators illuminates the distributed nature of memory processing in the brain, and provides new insights into the process of memory recall, which is less understood than memory storage.
A protein called CDC7, long thought to play an essential role early in the cell division process, is in fact replaceable by another protein called CDK1, according to a study by investigators at Weill Cornell Medicine and the Dana-Farber Cancer Institute.
Two multi-institutional teams led by Weill Cornell Medicine scientists have been awarded grant support from the Starr Cancer Consortium. Both grants will fund work applying new technologies to develop more detailed knowledge of tumor biology, with one team focusing on Hodgkin lymphoma and the other on the purity of tumor samples on pathology slides.
Investigators from Weill Cornell Medicine and Memorial Sloan Kettering Cancer Center have discovered how a drug for multiple sclerosis interacts with its targets, a finding that may pave the way for better treatments.
A protein that masterminds the way DNA is wrapped within chromosomes has a major role in the healthy functioning of blood stem cells, which produce all blood cells in the body, according to a new study from researchers at Weill Cornell Medicine.
A group of immune cells that normally protect against inflammation in the gastrointestinal tract may have the opposite effect in multiple sclerosis (MS) and other brain inflammation-related conditions, according to a new study by Weill Cornell Medicine and NewYork-Presbyterian researchers.
Antibody protection against harmful forms of fungi in the gut may be disrupted in some patients with Crohn’s disease—a condition caused by chronic inflammation in the bowel—according to a new study by Weill Cornell Medicine investigators.
COVID-19 may bring high risks of severe disease and death in many patients by disrupting key metabolic signals and thereby triggering hyperglycemia, according to a new study from researchers at Weill Cornell Medicine and NewYork-Presbyterian.